Shares of Innoviva Inc. (INVA), a diversified holding company with a portfolio of royalties and other healthcare assets, have lost nearly 14% of their value year-to-date to trade around $11.
The company's royalty portfolio is made up of respiratory assets partnered with Glaxo Group Limited including RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
The commercial and marketed products include GIAPREZA approved in the United States to increase blood pressure in adults with septic or other distributive shock, and XERAVA, approved in the U.S. for the treatment of complicated intra-abdominal infections in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.